| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01357642 | Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients | PHASE3 | COMPLETED | 373 | — | — | Jul 1, 2011 | Dec 1, 2011 | Mar 11, 2016 | 33 | United States |
| NCT01188577 | Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics | PHASE1 | COMPLETED | 23 | — | — | Aug 1, 2010 | Jan 1, 2011 | Jul 25, 2017 | 1 | United States |
| NCT01143051 | Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers | PHASE1 | COMPLETED | 24 | — | — | Jan 1, 2010 | Jun 1, 2010 | Sep 25, 2018 | 1 | United States |
Serial FEV1 measurements to demonstrate the mean AUC of change in percent FEV1 from same-day baseline of E004 (Treatment T; Epinephrine-HFA) versus Placebo-HFA (Treatment P) is the primary efficacy endpoint.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at Baseline (prior to dosing) in each treatment period following a specified washout period (3-14 days), and were analyzed using an established analysis method. Baseline concentration (C0) is the concentration of epinephrine measured in the plasma at this time point.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Peak (maximum) concentration (Cmax) is the highest concentration of epinephrine measured in plasma during the treatment period.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Area under the curve from time zero to 6 hours post-dose (AUC\[0-6\]) was calculated using the trapezoidal rule.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Tmax is the amount of time it takes for epinephrine to reach peak concentration in plasma during the treatment period.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Half-life (t1/2) is the amount of time it takes for epinephrine to decrease to half the peak concentration in plasma during the treatment period.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 2, 5, 7.5, 10, 12.5, 15, 20, 25, 30, 45, 60, 90, 120, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at Baseline (prior to dosing) in each treatment period following a specified washout period (3-14 days), and were analyzed using an established analysis method. Baseline concentration (C0) is the concentration of epinephrine measured in the plasma at this time point.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Area under the curve from time zero to 6 hours post-dose (AUC\[0-6\]) was calculated using the trapezoidal rule.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Peak (maximum) concentration (Cmax) is the highest concentration of epinephrine measured in plasma during the treatment period.
Patient PK blood samples were taken from a vein in a hand or arm via indwelling heparin-anticoagulated IV catheters, or by venipunctures at 0 (baseline), 5, 15, 30, 45, 60, 90, 120, 180, 240, and 360 minutes post-dose in each treatment period and were analyzed using an established analysis method. Half-life (t1/2) is the amount of time it takes for epinephrine decrease to half the peak concentration in plasma during the treatment period.
| Arm | Type | Description |
|---|---|---|
| Arm T | EXPERIMENTAL | Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals |
| Arm P | PLACEBO_COMPARATOR | Placebo comparator as 2×Placebo QID, with 4-6 hr intervals |
| Arm A | ACTIVE_COMPARATOR | Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals |
| Epinephrine Inhalation Aerosol, HFA | EXPERIMENTAL | Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a |
| Epinephrine Inhalation Aerosol, CFC | ACTIVE_COMPARATOR | Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations |
| Treatment C | ACTIVE_COMPARATOR | Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose. |
| Treatment 1 | EXPERIMENTAL | T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation |
| Treatment 2 | EXPERIMENTAL | HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation |
| Name | Type | Description |
|---|---|---|
| Epinephrine inhalation aerosol | DRUG | Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals |
| Placebo | DRUG | Placebo for epinephrine inhalation aerosol, formulation without epinephrine |
| Epinephrine Inhalation Aerosol, HFA | DRUG | 10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation |
Inclusion Criteria: * Patients with documented asthma, requiring inhaled epinephrine or beta 2-agonist treatment. * No significant changes in asthma therapy and no asthma-related hospitalization or emergency visits, within 4 weeks prior to Screening * Can tolerate withholding treatment with inhaled...